Michael Warrener has over 15 consecutive years of experience in the implantable radioactive microspheres space in treatment of liver cancer, joining Sirtex Medical in 2002 and in the treatment of pancreas cancer with Oncosil Medical. His responsibilities have been focused on the commercialisation of these innovative therapies and include 5 years with Sirtology where he focused on product design development, quality management, regulatory and design dossier submissions for CE Marking in the European Union. Mr Warrener moved from Sirtex Sydney to Bonn, Germany in 2003 as the European director of sales and marketing to establish the EU market, as well as Scandanavian countries and a number of middle eastern countries.